Fin Trust Capital Advisors, LLC Harmony Biosciences Holdings, Inc. Transaction History

Fin Trust Capital Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$19.2 - $33.78 $1,036 - $1,824	-54 Reduced 61.36%	34 $1,000
Q3 2023 Oct 24, 2023	SELL	$31.89 - $39.03 $76,759 - $93,945	-2,407 Reduced 96.47%	88 $2,000
Q4 2022 Feb 14, 2023	SELL	$45.4 - $60.91 $694,756 - $932,105	-15,303 Reduced 85.98%	2,495 $137,000
Q3 2022 Oct 20, 2022	BUY	$42.06 - $55.45 $1,430 - $1,885	34 Added 0.19%	17,798 $911,000
Q2 2022 Jul 26, 2022	SELL	$33.54 - $52.15 $16,669 - $25,918	-497 Reduced 2.72%	17,764 $906,000
Q1 2022 May 03, 2022	BUY	$33.14 - $51.13 $605,169 - $933,684	18,261 New	18,261 $888,000

242

45.1M

108K

49.2K

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.02B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

Get notified when there are updates to the investment portfolio of Fin Trust Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Fin Trust Capital Advisors, LLC with notifications on news.